Thursday, 20th November
|
|
|
- Darcy Pitts
- 8 years ago
- Views:
Transcription
1
2 Thursday, 20th November Opening remarks Carlos Camps, Hospital General Universitario, Valencia Past, present and future of the Spanish Lung Cancer Group SESSION 1 Cancer biology and lung cancer origins: improving knowledge for better treatment Is Helicobacter Pylori a cause of lung cancer? HPV in exhaled breath condensate of lung cancer patients Role of the SWI/SNF and MYC/MAX pathways in lung cancer development Complement activation pathway elements as diagnostic markers and therapeutic targets in NSCLC Luis Montuenga, Universidad de Navarra, Pamplona (Navarra) Florentino Hernando Trancho, Hospital Clínico San Carlos, Madrid Cristina Teixidó, Pangaea Biotech, Barcelona Cristina Queralt, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, L Hospitalet de Llobregat (Barcelona) Rubén Pío, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona (Navarra) Moving forward to solving the problem of predicting relapse in early NSCLC patients How to improve the outcome of SCLC patients: a message from a basic researcher SESSION 2 Liquid biopsy Circulating tumor cells in lung cancer. What is the reality? New promises in mrna and mutational analysis Ernest Nadal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Jun Yokota, Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona (Barcelona) Federico Rojo, Fundación Jiménez Díaz, Madrid Alexandra Voutsina, University of Crete, School of Medicine, Heraklion, Greece EGFR, KRAS, BRAF, MET, PIK3CA mutations and ALK translocations in blood platelets. A novel approach for diagnosis and monitoring Thomas Würdinger, VU University Medical Center, Amsterdam, The Netherlands EGFR mutations in circulating tumor DNA. The EURTAC experience KRAS and BRAF mutations in circulating tumor DNA Clara Mayo, Instituto Univ. USP Dexeus, Barcelona
3 Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group The role of SNPs in NSCLC Taking cancer cells out of circulation. Induction of patient-specific tumors in mice and prediction of response to chemotherapy Eloísa Jantus, Hospital General Universitario, Valencia Alberto Villanueva, ICO, Institut d Investigació Biomèdica de Bellvitge (Barcelona) Metabolomics by NMR facilitates the non-invasive diagnosis and staging of NSCLC Antonio Pineda, Centro de Investigación Príncipe Felipe, Valencia Lunch SESSION 3 Die another day: Targeted therapies in KRAS driven NSCLC KRAS mutations linked to poor prognosis and resistance to therapy State of art KRAS mutations in lung cancer KRAS mutations associated with folate pathway activity (tumor expression of MTHFD2 predicts response to pemetrexed) Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Rosario García-Campelo, Complejo Hospitalario Univ. A Coruña Autophagy dependence in KRAS driven tumors with production of secreted factors and Pivotal role for SMYD3 in the regulation of oncogenic Ras signaling Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona Small molecule inhibition of KRAS-PDE interaction impairing oncogenic KRAS signaling Roger Estrada, Universitat Ramon Llull, Barcelona Synthetic lethal combinations in KRAS NSCLC cell lines combining gefitinib/ erlotinib with an AXL inhibitor. Compound 16 Silvia García-Román, Universitat Ramon Llull, Barcelona What is the usefulness of p53 mutations in large cohorts of EGFR-mutated, EGFR TKI treated, or non-mutated chemotherapy treated lung cancer patients? Miguel Ángel Molina, Hospital Univ. Quirón Dexeus, Barcelona
4 Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group SESSION 4 The renaissance of customizing chemotherapy and targeted therapy New clues in ERCC1 prompting the PIPSeN study olaparib maintenance in platinum-sensitive NSCLC Juan Coves, Hospital Son Llàtzer, Palma de Mallorca Manuel Cobo, Hospital Univ. Carlos Haya, Málaga Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France The predictive role of BRCA1/53BP1 and HERC2 mrna in advanced NSCLC patients The emerging role of bridging molecules in BRCA complexes. Key role of PALB2 in the BREC Results of BRCA pathway analysis in the NATCH study The burning need to repurpose drugs in NSCLC and SCLC Biomarkers for exploiting the vulnerabilities of DNA repair deficiency or proficiency Coffee Break SESSION 5 Second and third generation EGFR TKIs State of the art in second generation EGFR TKIs: afatinib & dacomitinib State of the art in third generation EGFR TKIs: AZ9291, CO-1686, HM Lessons from the BELIEF Synthetic lethal therapy with EGFR TKIs plus repurposing drugs in EGFR mutant lung cancer customized by BIM mrna expression Laura Bonanno, Istituto Oncologico Veneto, Padova, Italy Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona Imane Chaib, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Mariacarmela Santarpia, Istituto Europeo di Oncologia, Messina, Italy Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo (Asturias) Manuel Dómine, Fundación Jiménez Díaz, Madrid Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Pilar Lianes, Hospital de Mataró, Mataró (Barcelona) Santiago Ponce, Hospital Univ. 12 de Octubre, Madrid Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Characterization of irreversible EGFR mutant selective EGFR inhibitors. What we need to know. Roger Estrada, Universitat Ramon Llull, Barcelona
5 Friday, 21st November SLCG Plenary Session SESSION 6 Recent result in advanced NSCLC Immune based anti-tumor therapies. PD1 & PDL1 blockade Antiantiogenic strategies ALK Target Therapies SESSION 7 Diagnostic clinical genome and exome sequencing Sequencing of the genome or exome for clinical applications Actionable diagnosis of lung cancer by next generation sequencing Treatment of ROS1 lung cancer patients: the EUCROSS trial Opportunities to treat other driver alterations such as RET and NTRK Treatment of BRAF mutant NSCLC patients Current practice in diagnostic clinical genome Coffee break Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Enriqueta Felip, Hospital General Vall d Hebron, Barcelona Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona Amelia Insa, Hospital Clínico Universitario, Valencia Angel Artal, Hospital Univ. Miguel Servet, Zaragoza Natividad Martínez, Hospital General Universitario, Elche (Alicante) Trever Bivona, University of California, San Francisco (California), USA Julie George, Center for Integrated Oncology, University of Cologne, Germany Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany Ignatius Ou, University of California Irvine Medical Center, Orange (California), USA José Miguel Sánchez, Hospital Univ. de La Princesa, Madrid Fernando López-Ríos, Centro de Investigaciones Oncológicas Clara Campal, Madrid
6 Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group SESSION 8 Moving forward to improving curability in locally advanced NSCLC. What s new? Salvage surgery following chemoradiotherapy How can we reconcile chemoradiotherapy with or without surgery for locally advanced NSCLC? Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Manuel de las Heras, Hospital Clínico San Carlos, Madrid Laura Romero, Hospital Univ. Vall d Hebron, Barcelona New opportunities to treat: RENO trial Novel expectations in chemoradiotherapy SESSION 9 Novel perspectives in management of early stage NSCLC SCAT results of customized adjuvant chemotherapy in state II and III resected NSCLC patients Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza Wilfried Eberhardt, West German Cancer Center, Essen, Germany Marcelo Jiménez, Hospital Universitario de Salamanca José Luis González Larriba, Hospital Clínico San Carlos, Madrid Bartomeu Massutí, Hospital General Universitario, Alicante Management of stage I NSCLC patients What we can expect in the next two years. The hope for SCLC and increased survival in NSCLC patients Javier de Castro, Hospital Univ. La Paz, Madrid Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) State of the art in mesothelioma Closing Remarks Noemí Reguart, Hospital Clínic Universitari, Barcelona
7 Scientific Committee Carlos Camps, Hospital General Universitario, Valencia Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Manuel Cobo, Hospital Univ. Carlos Haya, Málaga Juan Coves, Hospital Son Llàtzer, Palma de Mallorca Javier de Castro, Hospital Univ. La Paz, Madrid Manuel Dómine, Fundación Jiménez Díaz, Madrid Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña José Luis González Larriba, Hospital Clínico Univ. San Carlos, Madrid Florentino Hernando-Trancho, Hospital Clínico Univ. San Carlos, Madrid Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza Eloísa Jantús, Hospital General Universitario, Valencia Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona Bartomeu Massutí, Hospital General Universitario, Alicante Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) Noemí Reguart, Hospital Clínic Universitari, Barcelona Delvys Rodríguez, Hospital Univ. Insular de Gran Canaria, Las Palmas Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) José Javier Sánchez, Universidad Autónoma de Madrid José Miguel Sánchez, Hospital Univ. de la Princesa, Madrid Miquel Taron, Pangaea Biotech, Barcelona
8 Venue Hotel NH Eurobuilding Sala Madrid c/ Padre Damián, Madrid Holding a badge will be required to access the meeting room Language Lectures will be delivered in English or Spanish. Credits Accreditation requested to the Consell Català de Formació Continuada de les Professions Sanitàries Supporting Companies Symposium Secretariat Monasterios de Suso y Yuso 34, Madrid Tel.: gecp2014@doctaforum.com
Registrations: www.doctaforum.com/gecp
Chair: Rafael Rosell Under the Auspices of: Registrations: www.doctaforum.com/gecp Thursday, 21 st of November 2013 08:00-10:00 CLINICAL SESSION Isabel lbover Fundación Hospital Son Llàtzer, Palma de Mallorca
Chairs: Mariano Provencio. Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) Rafael Rosell
Chairs: Mariano Provencio Rafael Rosell ICO, Hospital Universitario Germans Trias i Pujol, Badalona (Barcelona) Under the auspices of: Registrations: www.doctaforum.com/gecp THURSDAY, 26 TH NOVEMBER NEW
Registrations: www.doctaforum.com/gecp
Organized by Registrations: www.doctaforum.com/gecp CHAIR Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Under the Auspicies of: Thursday, 17 th November 2011 SESSION 1:
Retrieval Centres for HPC-M and HPC-A
A Coruña - (Cod: ES0061) COMPLEXO HOSPITALARIO UNIVERSITARIO JUAN CANALEJO Estrada das Xubias, s/n - 15006 Alcalá de Henares MADRID - (Cod: ES0208) HOSPITAL UNIV. PRINCIPE ASTURIAS Carretera Alcalá-Meco,
Pharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN
D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra.
Nuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
Dialnet. Author Identification. Eduardo Bergasa eduardo.bergasa@unirioja.es
Dialnet Author Identification Eduardo Bergasa eduardo.bergasa@unirioja.es Fundación Dialnet! Public non-profit foundation! Spin-off of University of La Rioja! Constitution: 2009! In charge of Dialnet portal
Scientific Program. Advances in the Treatment of Digestive Tumours. Symposium. International. Under the auspices of: Accredited by:
Advances in the Treatment of Digestive Tumours Scientific Program 22 International Symposium Barcelona (Spain) 11th and 12th December 2014 HOTEL BARCELÓ SANTS Under the auspices of: FEDERATION OF SPANISH
INDUSTRY-ACADEMIC-CLINICAL FORUM
INDUSTRY-ACADEMIC-CLINICAL FORUM FUTURE TRENDS IN NANOMEDICINE FOR DIAGNOSTICS AND THERAPY IN ONCOLOGY Parc Científic de Barcelona / Barcelona Science Park 25 th of October of 2012 TABLE OF CONTENTS Agenda
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region
WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region April 2016 27-30 Santiago - Chile Hotel Diego de Almagro San Pío X 2530, Providencia, Santiago. INFORMATION www.lungcancerworkshop.cl
laura.bonanno@ioveneto.it Medical Oncology 2 Unit. Medical Oncology 2 Istituto Oncologico Veneto I.R.C.C.S
E UROPEAN C URRICULUM V ITAE PERSONAL DATA Name Laura Bonanno Work address Medical Oncology 2 I.O.V. Istituto Oncologico Veneto I.R.C.C.S. Via Gattamelata, 64 35128 Padova (IT) Telefono +390498215553/5931
Scientific Programme
Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico
HPC authorized transplant centres SPAIN
Last updated: 8/1/08 A Coruña - (Cod: ES0061) COMPLEXO HOSPITALARIO UNIVERSITARIO JUAN CANALEJO Estrada das Xubias, s/n - 15006 ALBACETE - (Cod: ES0062) COMPLEJO HOSPITALARIO Y UNIVERSITARIO DE ALBACETE
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
How To Contact Cotransa
COTRANSA - Key Contact Details Physical address: MADRID (HEAD OFFICE) Avda Central, Parcela 2.5, Naves 1 y 3. 28042 Centro de carga aerea Marid-Barajas Madrid (SPAIN) Tel: +34 917 46 06 80 Fax: +34 913
Targeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia
Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia Dr Jordi Sierra Gil IRHSP Institut de Recerca Hospital de la Santa Creu i Sant Pau Dr. Miguel Ángel Sanz Alonso Fundación
SCIENTIFIC PROGRAMME. Foundation
SCIENTIFIC PROGRAMME Foundation WEDNESDAY *Coffee-breaks will be in the Commercial Exhibition Areas All posters will be displayed on digital screens 4 5 THURSDAY 29 OCTOBER 8:00-9:00h CONGRESS HIGHLIGHTS
13 May 14 May. SESSION 2.- Advances in hearing loss research II Chair: Andrew Forge
13 May 14 May 15:00-17:00 Registration 15:45-16:00 Welcome on behalf of the organizers José María Millán. Unit of Genetics La Fé Hospital. CIBERER. Valencia. Spain. 16:00-16:30 Francesc Palau. CIBERER
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010
CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
15 th ASEICA INTERNATIONAL CONGRESS
Sevilla 21-23 october 2015 15 th ASEICA Spanish Society for Cancer Research Hotel NH Collection Sevilla. Avda Diego Martinez Barrio, 8, 41013 Sevilla Organizing Committee President Dr. Pedro Lazo-Zbikowski
Wednesday, February 24 th, 2016
List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
Promises and challenges of developing new drugs in oncology
3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San
Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom
Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom Luca Gianni Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy Ana Maria Gonzalez-Angulo M.D. Anderson Cancer
Future Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
Gastrointestinal Tumors
Gastrointestinal Tumors CHAIRMEN: A. Carrato B. Massutí ORGANIZING COMMITTEE: A. Abad A. Antón E. Aranda A. Cervantes E. Díaz-Rubio M. Navarro J.M. Tabernero A. Carrato B. Massutí IX TTD International
RIBS V. Fernando Alfonso MD, PhD, FESC Hospital Universitario La Princesa Madrid.
A Randomized Comparison of Drug-Eluting Balloon Versus Everolimus-Eluting Stent in Patients With Bare-Metal In-Stent Restenosis: The RIBS V Clinical Trial Fernando Alfonso MD, PhD, FESC Hospital Universitario
OCU's experience in adapting to the Spanish CV standard format (CVN)
OCU's experience in adapting to the Spanish CV standard format (CVN) Bolonia, 26 th May 2011 Roberto Moreno, Product Manager Manuel Rivera, Clients Manager info@ocu.es +34 91.382.21.40 Index About OCU
Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Focus on IBD
Marbella (Spain), January 29th & 30th, 2015 Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Preliminary Program Thursday, January 29th 2015 15:45-16:00 Welcome to the
Department of Haematology University Hospital. University of Salamanca, Spain
Immunophenotyping of Plasma Cells: Implications on management Department of Haematology University Hospital Cancer Research Centre J.F. San Miguel University of Salamanca, Spain Faculty disclosure information
Targeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
Speakers * * ** * * * * * * * * * * * * * * * * ** * * * * * * * ** * * * * ** * * * * * * ** * * * * * * * *
Quasispecies: past, present and future 30 th anniversary VIII Jornada de Virologia SCB November 17-18, 2008 Institut d Estudis Catalans, Barcelona, Spain Speakers Christof Biebricher Albert Bosch Carlos
10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio
10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving
Moving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient
Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that
targeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)
Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
CURRICULUM VITAE 11/10/04
CURRICULUM VITAE 11/10/04 Ariana Diana RUS MD. PRESENT POSITION 2000-present Department of Physiology Faculty of Medicine University of Valencia PhD Student Cl/ Avda. Blasco Ibanez, 15 C.P. 46010 Valencia
Developments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in
Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Expanding the Scope to IBD
Marbella (Spain), January 17th & 18th, 2013 Diagnostic and Therapeutic Colonoscopy for Colorectal Neoplasia in the 21st Century: Thursday, January 17th 2013 8:45-9:00 Welcome to the Hands-on Course Andres
Education Session 1. Education Session 2. Inaugural Session
WEDNESDAY 4 NOVEMBER 2015 Education Session 1 09:30-10:30 S1a: Cell and viral vector manufacturing and distribution under GMP Chair: Ana Sanchez S1b: Systems biology: computational methods applied to advanced
Social Cohesion in Europe
Social Cohesion in Europe February 4 th, 5 th, 2008 Universidad Carlos III de Madrid Scientific Committee: Gregorio Peces-Barba, Chairman (Universidad Carlos III de Madrid) Javier de Lucas (Director del
WORKSHOP ON THE CONSERVATION OF THE SUBTERRANEAN CULTURAL HERITAGE. Seville, Spain. 25-27 March 2014
WORKSHOP ON THE CONSERVATION OF THE SUBTERRANEAN CULTURAL HERITAGE Seville, Spain 25-27 March 2014 ORGANIZED BY TECHNOHERITAGE SPANISH NETWORK OF SCIENCE AND TECHNOLOGY FOR THE CONSERVATION OF CULTURAL
targeted cancer therapy
LUNG CANCER TREATMENTS What you need to know about... targeted cancer therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with
The EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl
eso InSIDe TrACK COnferenCe 6 TH familial CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl Dear Colleagues, The 6th Familial Cancer Conference hosted once
Liver. Meeting. International. on living donor. transplantation. After Fifteen Years (2000-2015)
Preliminary Program International Meeting ORGANIZED BY Hospital Clínic Hospital Universitari Vall d Hebron Liver Transplantation Units faculty Scientific committee Juan Carlos García-Valdecasas Ramón Charco
ADDARIO LUNG CANCER MEDICAL INSTITUTE
ADDARIO LUNG CANCER MEDICAL INSTITUTE Dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients. Contact: Steven
Payee Name Recipient Type Program/Project Description Support Type Country Currency
Z Grants & Donations for the second half of 2011 SPAIN Payee Name Recipient Type /Project Description Support Type Country Currency Individual Payment Amount Payment Date ACCIÓN PSORIASIS Patient Organization
AUDITORIUM ALFREDO KRAUS
AUDITORIUM ALFREDO KRAUS LAS PALMAS DE GRAN CANARIA JUNE 27-29th 2014 Organized by: Activity accredited by the Catalan Council for Continuing Medical Education 09/10879-MD 1,6 Credits groupgem.org Organizing
URO. 19/20 March 2015. 4 th International Workshop. Madrid
URO 2015 4 th International Workshop ADVANCED PROSTHETIC UROGENITAL SURGERY IN THE TREATMENT OF POST-RADICAL PROSTATECTOMY SEQUELAE Madrid 19/20 March 2015 Puerta de Hierro-Majadahonda University Hospital
Lung Cancer. Advances in Lung Cancer Treatment
Lung Cancer Advances in Lung Cancer Treatment Treatment for lung cancer is changing rapidly. There are new therapies that target specific molecular changes that drive the growth and spread of the lung
Robert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
STELLA 2014 Intercontinental Staff Mobility Programme
1. Brazil UNESP 1 000.00 Eliana Correa Contiero Board Academic 03/01 International Relations Office European Programs Coordination (Universidad Politécnica de Madrid, Spain) 2. Brazil UNESP 1 000.00 Ivani
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
Social Choice and Welfare Economics. Workshop. Málaga, May 29/31, 2003. Hotel Larios Meeting Room Marqués de Larios, 2 MÁLAGA
Workshop Social Choice and Welfare Economics Coordinators: Pablo Amorós González Bernardo Moreno Jiménez Socorro Puy Segura Carmen Beviá Baeza Humberto Llavador González Málaga, May 29/31, 2003 Hotel Larios
What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer
What s New in Ovarian Cancer Research? Novel Therapeutics for Ovarian Cancer Scott Kaufmann, M.D., Ph.D. Mayo Clinic Division of Oncology Research October 27, 2012 Where we are now. Surgery Front-line
A clinicians view on NGS of (lung) cancer
A clinicians view on NGS of (lung) cancer oliver.gautschi@onkologie.ch 14.1.2015 Predictive Role of Biomarkers for Lung Cancer Therapy Chemotherapy: not confirmed Anti-Angiogenic-Therapy: not confirmed
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C
ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium
September 6th 2010 (Monday) Centro de Docencia Hospital Universitario Miguel Servet. Aula Edificio Consultas Externas. C/.
UPDATE IN THE MANAGEMENT OF GAUCHER DISEASE AND OTHER LYSOSOMAL DISORDERS PROGRAMME September 6-9th, 2010 Co-Directors Program MD, PhD - Miguel Servet University Hospital. CIBERER Miguel Pocovi, Profesor
METIE. Theory and International. Master in Economic. Economics. Official University. Postgraduate. Program. Degree. Madrid.
Postgraduate Program Official University Degree Master/60 ECTS Executive Program Madrid METIE Master in Economic Theory and International Economics Summary METIE Program Objectives / 2 Structure / 2 Courses
Talentum Startups An Open Innovation Program. Javier Santiso Managing Director Global Affairs & New Ventures Telefónica, S.A.
Talentum Startups An Open Innovation Program Javier Santiso Managing Director Global Affairs & New Ventures Telefónica, S.A. December, 2013 Unemployment (%) (March, 2013, Eurostat) Innovation is growth
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
A novel molecular mechanism involved in cancer development revealed by targeting MafB to hematopoietic progenitors
A novel molecular mechanism involved in cancer development revealed by targeting MafB to hematopoietic progenitors Carolina Vicente Dueñas Instituto de Biología Molecular y Celular del Cáncer (IBMCC) (CSIC-Universidad
Scientific Program Call for Abstracts Registration Accommodation
SECOND ANNOUNCEMENT Scientific Program Call for Abstracts Registration Accommodation Deadline for abstract submission: September 20 th, 2011 www.madridbreastcancer2011.com Madrid, November 16-17, 2011
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
Genomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
Resolving Cancer Heterogeneity:
INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for
El papel de la anatomía patológica en oncología: presente y futuro. The role of pathological anatomy in oncology: present and future
El papel de la anatomía patológica en oncología: presente y futuro The role of pathological anatomy in oncology: present and future Federico Rojo Fundación Jiménez Díaz, Madrid All patients with same diagnosis:
How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor
FAK INHIBITOR DEFACTINIB (VS-6063) TARGETS MESOTHELIOMA CANCER STEM CELLS Rationale for maintenance therapy after conventional therapy Jonathan Pachter, Ph.D. Vice President of Research, Verastem, Inc.
New Directions in Treatment of Ovarian Cancer. Amit M. Oza Princess Margaret Hospital University of Toronto
New Directions in Treatment of Ovarian Cancer Amit M. Oza Princess Margaret Hospital University of Toronto Newly diagnosed: scenario Ist line Surgery chemotherapy Cure If can t cure can we turn into chronic
30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens
Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.
SCIENTIFIC SECRETARY. - Richard Baird, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
PROGRAM CHAIRMEN - Bruce A. Chabner, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA - Hernán Cortés-Funes, Hospital Universitario 12 de Octubre, Instituto de Investigación i+12,
How To Learn More About Melanoma
PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard
WORKSHOPS CURRE T TRE DS I BIOMEDICI E
WORKSHOPS CURRE T TRE DS I BIOMEDICI E 2013 SEDE A TO IO MACHADO BAEZA, SPAI MEMBRA E TRAFFIC AT THE SY APSE. THE CELL BIOLOGY OF SY APTIC PLASTICITY Baeza, Spain 7 th -9 th October 2013 Organized by:
BIOGRAPHY OF THE MEMBERS OF THE AIREF ADVISORY BOARD
BIOGRAPHY OF THE MEMBERS OF THE AIREF ADVISORY BOARD RAFAEL ÁLVAREZ BLANCO Rafael Álvarez Blanco was director of the department of statistics and central balance sheets at the Bank of Spain for 24 years
DRAFT PROGRAMME Transbio Valencia event
DRAFT PROGRAMME Transbio Valencia event February 27th and 28th Field Study Best practices for company creation and development Workshop Housing & access to technologies for biotech companies Calendar February
LIQUID BIOPSY: TRACKING CANCER
SYMPOSIUM LIQUID BIOPSY: TRACKING CANCER 29-30 April 2016 first announcement Pierre-Auguste Renoir Chemin montant dans les hautes herbes Organizing Secretariat CONGRESS LINE Via Cremona, 19-00161 Rome
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10
ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline
Madrid International Bariatric Endoscopy
2 nd international course Madrid International Bariatric Endoscopy www.mibemeeting.com MIBE 2015 Madrid International Bariatric Endoscopy 24 th and 25 th 2015 September Madrid Sanchinarro University Hospital
Targeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku
11 th International Congress on Targeted Anticancer Therapies Paris March 4-6, 2013 Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku Investigational Cancer Therapeutics (Phase
UCM Quick Facts 2014-2015
UCM Quick Facts 2014-2015 Departamento de Estudios e Imagen Corporativa STUDENTS ACADEMIC YEAR 2013-2014 Total Official Enrolment 81,218 Enrolment in UCM Centers 72,454 Bachelor s s 49,383 Year s and Higher
INTERNATIONAL CONGRESS:
VIGO, 2-3 July 2015 Club Financiero Avda. de García Barbón, 62 36.201 Vigo (Pontevedra) INTERNATIONAL CONGRESS: WORK AT SEA: NEW MARITIME LEGAL SCENARIOS Collaborating institutions: Jean Monnet European
Mediterranean School of Oncology
Mediterranean School of Oncology Organized and supported by: CINBO Consorzio Interuniversitario Nazionale per la Bioncologia HIGHLIGHTS IN THE MANAGEMENT OF COLORECTAL CANCER, February 1-2, 2007 Domus
NIVERSITIES. Memorandum on Cooperation in Higher Education. Council of Universities of Spain Ministry of Education, Culture and Sport.
NIVERSITIES ~ GOBIERNO DE EDUCACI6 N. CULTURA 06C..0'I1 ~taan I AO YDEPO RTE Memorandum on Cooperation in Higher Education Between Universities Australia Council of Universities of Spain Ministry of Education,